Literature DB >> 16187942

Resetting the functional capacity of regulatory T cells: a novel immunotherapeutic strategy to promote immune tolerance.

Lucienne Chatenoud1, Jean-François Bach.   

Abstract

Over the last few years, there has been a re-emergence of the concept of suppressor/regulatory T cells among the central players of immune mechanisms controlling a wide variety of immune responses from physiological autoreactivity (i.e., response to self-antigens) to responses to transplants, tumours and infectious antigens. Regulatory T cells are diverse in their phenotypes, antigen specificity, mode of action and immunopathological relevance. This review briefly summarises studies from the authors' group showing that specialised subsets of regulatory T cells are instrumental in the control of autoimmune diseases and more specifically of Type 1 diabetes. In addition, this review will provide evidence supporting the notion that CD3-specific monoclonal antibodies are representatives of a new category of immunotherapeutic agents that possess the unique capacity to promote immunological tolerance (an antigen-specific unresponsiveness in the absence of long-term generalised immunosuppression) through their ability to induce immunoregulatory T cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16187942     DOI: 10.1517/14712598.5.1.s73

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  2 in total

1.  Anti-TCR therapy combined with fingolimod for reversal of diabetic hyperglycemia by β cell regeneration in the LEW.1AR1-iddm rat model of type 1 diabetes.

Authors:  Anne Jörns; Muharrem Akin; Tanja Arndt; Taivankhuu Terbish; Andreas Meyer Zu Vilsendorf; Dirk Wedekind; Hans-Jürgen Hedrich; Sigurd Lenzen
Journal:  J Mol Med (Berl)       Date:  2014-03-07       Impact factor: 4.599

2.  Human cord blood stem cell-modulated regulatory T lymphocytes reverse the autoimmune-caused type 1 diabetes in nonobese diabetic (NOD) mice.

Authors:  Yong Zhao; Brian Lin; Robert Darflinger; Yongkang Zhang; Mark J Holterman; Randal A Skidgel
Journal:  PLoS One       Date:  2009-01-19       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.